Celsion (NASDAQ:CLSN) issued its earnings results on Wednesday. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.10, Fidelity Earnings reports. Celsion had a negative net margin of 1,653.20% and a negative return on equity of 57.46%.
NASDAQ:CLSN opened at $0.97 on Thursday. Celsion has a 52-week low of $0.69 and a 52-week high of $2.53. The company has a quick ratio of 2.58, a current ratio of 2.58 and a debt-to-equity ratio of 0.67. The stock has a fifty day simple moving average of $1.13 and a 200-day simple moving average of $1.48. The company has a market capitalization of $20.70 million, a PE ratio of -2.85 and a beta of 1.89.
A number of equities research analysts recently weighed in on CLSN shares. Zacks Investment Research cut Celsion from a “strong-buy” rating to a “hold” rating in a report on Friday, January 17th. ValuEngine cut Celsion from a “buy” rating to a “hold” rating in a report on Wednesday, March 11th.
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.
See Also: What is a trade deficit?
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.